Review Article
Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS
Table 6
Saxagliptin polled phase 2b/3 MACE [
13].
| | Events (%): saxagliptin/placebo | OR (95% CI) |
| Sponsor MACE | 0.5/1 | 0.5 (0.2–1.2) | Custom MACE (ST) | 0.1/0.6 | 0.21 (0.04–0.8) | Custom MACE (ST + LT) | 0.7/1.3 | 0.52 (0.3–1.0) | SMQ MACE (ST) | 1.8/2.0 | 0.90 (0.6–1.5) | SMQ MACE (ST + LT) | 3.1/3.2 | 0.96 (0.7–1.4) |
|
|